Core Insights - Curanex Pharmaceuticals Inc. has engaged Strategic Investor Relations, LLC to enhance its visibility and investor engagement in the financial community [1][2] - The company is focused on developing botanical drugs for inflammatory diseases, with a robust pipeline targeting conditions such as Ulcerative Colitis, Atopic Dermatitis, and Gouty Arthritis [3][6] - Curanex's lead candidate, Phyto-N, is a botanical extract with a long history of use in China and is set for IND submission in 2026 [3][6] Company Overview - Curanex Pharmaceuticals is a developmental-stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases [6] - The company has validated Phyto-N's effects in animal models for six inflammatory diseases, with a primary focus on moderate to severe ulcerative colitis [7] Strategic Initiatives - The partnership with Strategic Investor Relations aims to refine communication strategies and enhance transparency with stakeholders [2][5] - Curanex's founders have a strong foundation in botanical drug innovation, leveraging over 30 years of clinical evidence from China to inform their development processes [4] Market Positioning - Curanex is positioned in the rapidly expanding botanical drug market, focusing on high-efficacy botanical drugs with de-risked clinical pathways [2][5] - The company aims to communicate its innovative pipeline and market opportunities more effectively to drive shareholder value [5]

As filed with the Securities and Exchange Commission on June 21, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | --- | ...

As filed with the Securities and Exchange Commission on December 5, 2023 Registration Statement No. 333-274042 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | ...